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AbsTrACT
Cerebral amyloid angiopathy (CAA) has never been 
more relevant. The last 5 years have seen a rapid 
increase in publications and research in the field, with 
the development of new biomarkers for the disease, 
thanks to advances in MRi, amyloid positron emission 
tomography and cerebrospinal fluid biomarker analysis. 
The inadvertent development of CAA-like pathology 
in patients treated with amyloid-beta immunotherapy 
for Alzheimer’s disease has highlighted the importance 
of establishing how and why CAA develops; without 
this information, the use of these treatments may 
be unnecessarily restricted. Our understanding of 
the clinical and radiological spectrum of CAA has 
continued to evolve, and there are new insights into 
the independent impact that CAA has on cognition in 
the context of ageing and intracerebral haemorrhage, 
as well as in Alzheimer’s and other dementias. while 
the association between CAA and lobar intracerebral 
haemorrhage (with its high recurrence risk) is now well 
recognised, a number of management dilemmas remain, 
particularly when considering the use of antithrombotics, 
anticoagulants and statins. The Boston criteria for CAA, 
in use in one form or another for the last 20 years, are 
now being reviewed to reflect these new wide-ranging 
clinical and radiological findings. This review aims to 
provide a 5-year update on these recent advances, as 
well as a look towards future directions for CAA research 
and clinical practice.
InTroduCTIon
Cerebral amyloid angiopathy (CAA), a cerebral 
small vessel disease (SVD) characterised by the pres-
ence of amyloid-beta (Aβ) protein within cortical 
and leptomeningeal blood vessel walls,1 is a condi-
tion of increasing clinical and mechanistic impor-
tance. Although recognised pathologically since the 
early 20th century, CAA had been sidelined until 
it was more firmly associated with lobar intracere-
bral haemorrhage (ICH) many years later.2 3 This, 
together with the use of blood-sensitive magnetic 
resonance sequences to visualise asymptomatic 
haemorrhagic events that far exceed those causing 
clinical symptoms, has expanded our understanding 
of what CAA is and its clinical significance.2–4 The 
last 5 years have seen ongoing progress in this area, 
thanks in part to the development of new tech-
nologies within the fields of magnetic resonance, 
amyloid positron emission tomography ligands 
and cerebrospinal fluid (CSF) biomarker analysis.4 
Furthermore, CAA gained new relevance with the 
advent of anti-Aβ immunotherapies for the treat-
ment of Alzheimer’s disease (AD), as a sizeable 
proportion of those treated went on to develop 
imaging features of CAA-related inflammation as 
an unintended consequence.5 This, together with 
advances in our understanding of the impact of 
CAA on cognition, in the context of ICH, ageing 
and AD, has broadened the clinical spectrum 
of disease to which the contribution of CAA is 
recognised. The 5th International CAA Conference, 
held in Boston, Massachusetts in September 2016 
(https:// caaforum. org/ event/ 5th- international- caa- 
conference- 2016- boston- ma/), highlighted many of 
these developments, as well as a need to update the 
current diagnostic Boston criteria to better reflect 
these new wide-ranging clinical and radiological 
findings.
This review aims to provide a clinically oriented 
update on these recent advances, focusing on those 
in the last 5 years, since our last comprehensive 
review.3 Specifically, we will focus on newly identi-
fied biomarkers for CAA and their potential mecha-
nistic implications, as well as the latest insights into 
the pathophysiology and causes of CAA. We will 
also report on the expanding spectrum of clinical 
presentations associated with CAA, before finally 
considering the ongoing management dilemmas 
that face physicians working in neurology, elderly 
care and stroke medicine, among others, when 
faced with this disease.
bIomArkers AdvAnCes And meChAnIsTIC 
InsIghTs
Insights from hereditary cerebral haemorrhage 
with amyloidosis-dutch type (hChWA-d)
Establishing the natural history of sporadic CAA 
is difficult, in part due to the limited sensitivity of 
our current diagnostic criteria,6 7 and also due to 
the high prevalence of comorbid changes caused 
by ageing and other neurodegenerative disorders. 
Moreover, most of these clinical and radiological 
features are thought to occur  relatively late in the 
disease process; given that any potential window 
for treatment is likely to be at earlier stages of the 
disease, this is likely to significantly limit their use 
as feasible biomarkers.
HCHWA-D is an autosomal dominant disease 
that predominantly occurs in a limited number 
of families in the villages of Katwijk and Scheve-
ningen in the Netherlands.8 A point mutation 
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(E693Q) of the amyloid precursor protein (APP) gene9 leads 
to extensive Aβ deposition in the cortical and leptomeningeal 
arterioles and arteries. The underlying pathology of these Aβ 
deposits is similar to that in sporadic CAA with minimal or 
no neurofibrillary pathology.8 9 Most importantly, mutation 
carriers develop symptoms (recurrent ICH and dementia10) 
relatively early in life, usually between the ages of 50 and 60 
years. Therefore, using HCHWA-D as a model allows CAA-re-
lated changes to be studied with minimal confounding by 
comorbidities associated with ageing. This genetic condition 
also opens the possibility to find new disease markers, even in 
the presymptomatic phase.
Previous studies have shown that the characteristic radio-
logical signs of sporadic CAA are mimicked in symptomatic 
HCHWA-D, namely numerous lobar microbleeds with or 
without cortical superficial siderosis (cSS).3 11 12 In presymp-
tomatic HCHWA-D, haemorrhagic changes are present, but 
more subtle; in recent studies, none or only one of the ‘clas-
sical’ signs (lobar microbleeds, macrohaemorrhage, cSS or 
convexity subarachnoid haemorrhage, cSAH) were present.13 
However, other disease markers such as white matter hyperin-
tensities (WMH) and cortical microinfarcts, which are ischaemic 
manifestations of CAA,3 were  already prevalent among presymp-
tomatic HCHWA-D subjects.13 This indicates that these disease 
manifestations are among the earliest markers of the hereditary 
form of CAA and precede ICH. In addition to explicit white 
matter changes, the grey matter is also specifically but subtly 
affected; recent data clearly showed that both patients with CAA 
and HCHWA-D demonstrate similar patterns of cortical thin-
ning, suggesting that vascular Aβ is an independent contributor 
to cortical atrophy (figure 1).14
Vascular reactivity is measured by blood-oxygen level-depen-
dent (BOLD) amplitude, time to response and time to return to 
baseline after visual stimulation. Cerebrovascular dysfunction is 
intrinsically associated with CAA disease pathology by Aβ depo-
sition in the vessel wall, resulting in impaired vascular reactivity 
in symptomatic patients with CAA.15 Recently it was shown 
that similar changes are also present in symptomatic HCHWA-
D.16 Determination of vascular reactivity in symptomatic 
and presymptomatic HCHWA-D showed that in both groups 
vascular reactivity was significantly decreased in the occipital 
lobe.16 Although this effect was far more pronounced in the 
symptomatic group, raising the possibility that these effects may 
be influenced by the presence of occipital macrohaemorrhage, 
the finding of reduced vascular reactivity even in presymptom-
atic patients with HCHWA-D suggests it as an early step in CAA 
pathogenesis.
Both the haemorrhagic and haemodynamic cerebral changes 
are secondary effects of Aβ deposition in the cerebrovascular 
vessel wall17; a key future goal is to determine the level of Aβ 
deposition in the vessel wall itself. Measurement of Aβ species in 
the CSF shows reductions in both Aβ40 and Aβ42 in presymp-
tomatic as well as symptomatic patients with HCHWA-D.18 
These findings point to Aß deposition as another marker of the 
earliest phase of CAA-related pathology, occurring before clin-
ical or radiological findings appear.
In summary HCHWA-D appears to be an excellent model 
to study important aspects of CAA, particularly presymptom-
atic brain imaging changes, which are much more difficult to 
investigate in sporadic CAA. With further biomarker develop-
ment, HCHWA-D might also have promise for testing potential 
new disease-modifying therapies with potential relevance for 
sporadic CAA.
related developments in sporadic CAA
Imaging
Neuroimaging remains a central component to the diagnosis of 
CAA, with a focus on the presence of the haemorrhagic mani-
festations of the disease: lobar macrohaemorrhage, strictly lobar 
microbleeds and cSS.6 7 The last 5 years have seen increased 
understanding of these markers, as well as the emergence of new 
potential structural and functional imaging markers for CAA, all 
of which may be of both diagnostic and mechanistic relevance. 
Some notable recent advances are summarised here (table 1).19–30
While multiple lobar ICH remains the strongest indicator for 
CAA, they are a late feature of the disease and may not be a prac-
tical outcome marker for clinical trials.31 The association between 
cSS and CAA is now well recognised, reflected by its inclusion 
in the modified Boston criteria.7 Clinically, cSS is associated with 
transient focal neurological episodes (TFNE)32 and an increased 
risk of ICH,33–35 including early recurrent ICH.36 There is also 
increasing evidence that cSS is associated with cognitive impair-
ment, although it is not clear whether this is because cSS is a 
marker of severe CAA or because it has direct and independent 
effects on cognition.37–45 The other haemorrhagic marker of 
CAA, the presence of strictly lobar microbleeds, remains central 
to diagnosis. However, recent work reviewing diagnostic accu-
racy of using strictly lobar microbleeds alone found that while 
they were strongly predictive of CAA in a hospital cohort, this 
was not the case in a healthy community population.46 This has 
highlighted the importance of identifying new imaging markers 
for CAA that can further improve the specificity and sensitivity 
of diagnosis,31 47 particularly outside ICH cohorts.
In the last 5 years new structural and functional imaging 
markers for CAA have emerged. As highlighted in a recent 
review,31 identifying new markers that could be used in thera-
peutic clinical trials is an urgent priority for CAA. Establishing 
CAA severity using neuroimaging also remains a challenge; a 
composite score has been proposed,48 which aims to estimate 
the overall pathological ‘burden’ of CAA in a given patient by 
combining key imaging markers of CAA, with some prelimi-
nary pathological verification of the concept. Evaluating this 
score against meaningful clinical outcomes will be essential for 
establishing whether it adds to the predictive value of individual 
markers or has practical application in clinical practice or future 
trials.
Body fluid biomarkers in sporadic CAA
Since CAA may arise due to the impaired clearance of Aβ from 
interstitial cerebral fluid, CSF should contain biomarkers that 
reflect this process. A key factor in understanding the signifi-
cance of the biomarkers in CSF will be to identify exactly the 
pathways for clearance of peptides from the interstitial fluid into 
the CSF.
It has been demonstrated that CAA-affected vessels, unlike 
senile plaques, contain significant Aβ40 in addition to Aβ42,49 
which is abundantly found in senile plaques. This specific 
pattern of Aβ40/42 deposition in CAA is reflected by decreased 
levels of both Aβ40 and Aβ42 peptides in CSF obtained from 
patients with CAA, diagnosed according to the Boston criteria50 , 
a  finding replicated by other groups.51 Similarly, decreased CSF 
Aβ40 and Aβ42 concentrations were observed in patients with 
isolated cSS.52 A rare variant of CAA is CAA-related inflamma-
tion (CAA-ri), also known as Aβ-related angiitis. Patients with 
this condition suffer from acute or subacute neurological impair-
ment, often including headache, encephalopathy, behavioural 
changes, seizures and focal neurological deficits. During the 
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Figure 1 Differences in cortical thickness between patients with (A) hereditary cerebral haemorrhage with amyloidosis–Dutch type and (B) sporadic 
cerebral amyloid angiopathy, and their respective age-matched controls. A general linear model was computed to schematically explore the regional 
differences in cortical thickness between patients with (A) HCHwA-D and healthy controls and (B) sporadic CAA and healthy controls, after adjusting 
for age and sex. Topographic surface maps were generated using a threshold of p<0.01 (with false discovery rate correction for multiple comparisons). 
The resulting maps show the statistically significant regional differences in cortical thickness. CAA, cerebral amyloid angiopathy; HCHwA-D, hereditary 
cerebral haemorrhage with amyloidosis–Dutch type; L, left; R, right. These panels have been reproduced without modification from14 (DOi: 10.1016/S1474-
4422(16)30030-8), under the terms of the Creative Commons Attribution-NonCommercial-No Derivatives License (CC BY NC ND; https://creativecommons.
org/licenses/by-nc-nd/4.0/legalcode).
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acute phase of CAA-ri, increased levels of anti-Aβ autoantibodies 
can be found in the CSF,53 as well as decreased Aβ40 and Aβ42 
levels.54
In single case reports of CAA caused by the Dutch-type Aβ 
E22Q mutation and the Iowa-type Aβ D23N mutation, simi-
larly decreased levels of Aβ40 and Aβ42 peptides were found 
in CSF50; the results of larger studies suggest that these peptides 
might be promising preclinical markers of CAA, as discussed in 
the preceding section on HCHWA-D.18 Decreasing CSF Aβ40 
concentrations in these patients were associated with higher 
lobar microbleed count, increasing WMH volume and presence 
of cSS, and in addition were visible prior to the abnormali-
ties present on neuroimaging.
As expected, levels of both total and phosphorylated tau 
protein are not specifically related to CAA and were marginally 
elevated in CSF from patients with CAA compared with controls, 
but were substantially lower than in patients with AD.50 51 54 
Total tau protein levels are increased in CAA-ri, but both normal 
and increased levels of phosphorylated tau proteins have been 
described.51 53 54 These minor elevations in CSF tau protein 
levels are probably attributable to a low level of concomitant 
AD pathology (neurofibrillary tangles) in patients with CAA. In 
contrast to the observations in sporadic CAA, both CSF total tau 
and phosphorylated tau concentrations were decreased in symp-
tomatic, but not in presymptomatic patients with HCHWA-D 
compared with controls, although the difference in total tau 
disappeared after correction for age.18
Given the association of CAA with AD, CSF Aβ protein levels 
have also been studied in correlation with the presence of CAA 
in patients with dementia, in which strictly lobar microbleeds on 
MRI (T2* or susceptibility weighted imaging, SWI) were used 
as the indicator of CAA. An independent correlation between 
decreased CSF Aβ42 and the presence of cortical microbleeds 
was demonstrated in a heterogeneous cohort of patients with 
dementia.55 Patients with AD and with multiple microbleeds 
(defined as more than 8) also had lower CSF Aβ42 levels, 
compared with patients with AD without microbleeds,56 but 
such differences were not found for CSF Aβ40 levels.56–58 This is 
in contrast with recent data that showed reductions in both CSF 
Aβ40 and Aβ42 in patients with AD and strictly lobar microbleeds 
compared with those with AD without microbleeds.59
By contrast with CSF biomarkers, studies on the association 
between blood levels of Aβ proteins and the presence of CAA are 
rather limited. In patients with sporadic CAA, plasma Aβ40, but 
not Aβ42, concentrations were associated with WMH,60 indi-
cating that circulating Aβ peptides might be an indicator of cere-
bral microvascular damage. Moreover, in patients with multiple 
CAA-related ICH, both plasma Aβ42 and Aβ40 concentrations 
were higher than in controls.61 A single study described that 
plasma Aβ42, but not Aβ40, levels were decreased in patients 
with HCHWA-D.10
Together, these data highlight the promise that body fluid 
biomarkers hold as potential preclinical markers for CAA. 
Further work, in particular in identifying viable plasma 
biomarkers, is needed.
The pAThophysIology oF vAsCulAr Aβ deposITIon: An 
updATe
perivascular Aβ clearance
The deposition of Aβ in the basement membranes of cerebral 
capillaries and arteries maps the intramural perivascular drainage 
pathways.62 63 When physiological small volumes of Aβ40 or 
other solutes are injected into the grey matter of experimental 
rodent brains, the Aβ40 enters basement membranes of capil-
laries and basement membranes surrounding smooth muscle cells 
Table 1 Summary of potential new structural and functional imaging markers for CAA
Imaging marker evidence of potential as a biomarker in CAA limitations
MRI visible perivascular 
spaces in the centrum 
semiovale (CSO-PVS)
 ► Severe or high-grade CSO-PVS commonly observed in CAA19–22
 ► Pilot data show that, in those with CAA, CSO-PVS severity is associated with Aβ 
burden (as measured by PiB)23
 ► Non-specific (age-related); present in a number of 
other conditions24
Cortical atrophy  ► Thinner cortices in those with sporadic CAA compared with healthy controls; 
occipital, temporal, posterior parietal and medial frontal areas affected14 
(figure 1)
 ► Difficult to differentiate between atrophy secondary 
to parenchymal Aβ and that due to vascular Aβ in 
sporadic CAA
Visual functional MRI  ► Patients with CAA have abnormal BOLD responses to a visual stimulus 
(alternating checkerboard), with reduced response amplitude and prolonged time 
both to peak and to baseline15 25
 ► Those with CAA show a decline in BOLD amplitude that is detectable at 1 year; 
longitudinal difference in BOLD amplitudes was significantly lower in CAA 
compared with controls26
 ► Potentially of interest as a surrogate marker of vascular health in clinical trials
 ► Clinical implications of this remain unclear; due to 
technical factors at this stage, this is predominantly 
a research tool limited to academic medical centres
Network measures  ► Lower global efficiency of brain network in those with CAA; occipital, parietal 
and posterior temporal lobes most affected103
 ► Reduced efficiency correlated with Aβ burden (as measured by PiB) and impaired 
executive function and processing speed103
 ► Global efficiency shows a longitudinal decline with time (1.3 years) in those with 
CAA, and is associated with deteriorating executive function104
 ► Difficult to differentiate between network effects of 
parenchymal Aβ versus those due to vascular Aβ in 
sporadic CAA
 ► Mainly a research tool limited to academic medical 
centres
Amyloid PET imaging using 
[11C] PiB-PET and [18F] 
compounds
 ► In those with CAA, regions with high PiB retention area associated with 
subsequent haemorrhage27
 ► Although PiB-PET may not reliably distinguish between patients and age-
matched controls,28 early phase (1–6 min) uptake can do this29
 ► The occipital/posterior cingulate ratio of PiB uptake is different for those with 
CAA versus those with AD29
 ► PiB-PET and [18F] florbetapir binding is able to distinguish between CAA-
associated ICH and hypertension-associated ICH30
 ► Amyloid PET unable to differentiate between 
vascular and parenchymal Aβ
 ► Diagnostic accuracy for CAA seems limited
 ► Few data on change over time in CAA
Aβ, amyloid-beta; AD, Alzheimer’s disease; BOLD, blood-oxygen level-dependent; CAA, cerebral amyloid angiopathy; ICH, intracerebral haemorrhage; PET, positron emission 
tomography; PiB, Pittsburgh B compound.
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of arteries within 5 min of intracerebral injection, mirroring the 
deposition of Aβ in CAA.64 Vascular basement membranes are 
specialised forms of extracellular matrix, composed of glycopro-
teins such as collagen IV and laminin, as well as proteoglycans 
such as agrin and perlecan. With increasing age and with posses-
sion of ApoE ε4 genotype, vascular basement membranes change 
their composition, with reduced functional efficiency.65 66 The 
perivascular drainage of solutes is thus impaired in ageing and 
with possession of ApoE ε4, further adding to the burden of 
failure of other clearance mechanisms.65–68
Indeed, apart from intramural perivascular drainage, other 
mechanisms of breakdown and clearance of Aβ from the brain 
include enzymatic breakdown, clearance via the low-density 
lipoprotein receptor-related protein 1 (through which most of 
Aβ is cleared), and phagocytosis by perivascular macrophages, 
astrocytes or microglia.69–72 Possession of ApoE ε4 and ageing 
impact adversely on all these molecular and cellular clearance 
mechanisms, as well as on ATP-binding cassette transporters 
involved in the clearance of Aβ.73–75
The convective influx of CSF into the brain parenchyma has 
also received attention recently in relation to the clearance of 
Aβ.76 When horseradish peroxidase or fluorescent Aβ are injected 
into the CSF, they are observed in the walls of both arteries and 
veins at 30 min after injection into the CSF.77 78 As this process 
depends on optimal expression of aquaporin 4 forming chan-
nels present in the astrocyte end feet — and regulating water 
exchange — it has been named ‘glymphatic’ drainage. On a 
closer look using nanoparticles injected into the CSF and elec-
tron microscopy, the pial-glial basement membranes of arteries 
have been defined as the pathways for convective influx — or 
glymphatic drainage — of CSF into the cerebral parenchyma, 
with nanoparticles entering the brain within 5 min of their injec-
tion into the CSF compartment.79 It is difficult to interpret the 
relevance of this pathway in the context of pathogenesis of CAA, 
as Aβ is produced within the parenchyma and drains towards 
the leptomeningeal surface of the brain. The interplay between 
intramural drainage of interstitial fluid from the parenchyma 
along the basement membranes surrounding smooth muscle 
cells and the convective influx (or glymphatic drainage) of CSF 
along the pial-glial basement membranes into the parenchyma 
thus remains to be investigated further, as it probably plays a key 
role in the maintenance of homeostasis of the brain and in the 
development of diseases of Aβ accumulation80 (figure 2).81
Amyloid-related imaging abnormalities (ArIA): friend or foe?
Further insights into how and why CAA may occur have come 
from the recent immunotherapy trials for AD. All such trials have 
reported ‘Amyloid Related Imaging Abnormalities’ (ARIA) as an 
unintended adverse effect; these are defined by their neuroim-
aging appearances as either predominantly oedematous or haem-
orrhagic, with the former showing vasogenic oedema and the 
latter developing cerebral microbleeds and cSS.5 ARIA shares a 
striking similarity of imaging features with the rare inflamma-
tory variant of CAA (CAA-ri) in which spontaneously generated 
antibodies against vascular Aβ are observed.53 82 This apparent 
antibody-mediated development of imaging features found in 
CAA raises the possibilities that CAA may either develop as a 
consequence of rapid removal of parenchymal Aβ or trigger 
ARIA if already present when exposed to anti-Aβ antibodies. 
Higher and more effective doses of Aβ immunotherapy are more 
likely to result in ARIA,5 83 84 and areas affected by ARIA are 
associated with subsequent parenchymal Aβ clearance.5 85 86 The 
persistence of CAA after immunisation against Aβ42 suggests 
that the solubilised Aβ from plaques becomes entrapped in the 
intramural periarterial drainage pathways. Recent neuropatho-
logical work found that sites of microhaemorrhage are asso-
ciated with lower levels of vascular Aβ and less severe CAA,87 
which again may suggest that the neuroimaging findings seen 
in ARIA and associated with CAA might be manifestations of 
attempted Aβ clearance. The pathophysiological process by 
which parenchymal Aβ shifts to the vasculature may be medi-
ated by ApoE, which is involved both in Aβ transfer across the 
blood–brain barrier and intramural periarterial Aβ transport85; 
this could explain the increased incidence of ARIA events in 
those with the ApoE ε4 allele.88 Aβ immunotherapy seems to 
result in a shift in ApoE localisation that mirrors Aβ movement, 
with reductions in plaque-associated ApoE and an increase in 
cerebrovascular expression.85 However, the clinical relevance of 
ARIA remains unclear, since in one recent small immunotherapy 
Figure 2 Drainage pathways for CSF and interstitial fluid (iSF) to cervical 
lymph nodes. with permission from engelhardt et al.81 CSF and iSF drain to 
lymph nodes by different and distinct pathways. in humans, CSF drains into 
the blood of venous sinuses through well-developed arachnoid villi and 
granulations (AG). Lymphatic drainage of CSF occurs via nasal and dural 
lymphatics and along cranial and spinal nerve roots (outlined in green). 
Channels that pass from the subarachnoid space through the cribriform 
plate allow passage of CSF (green line) T cells and antigen presenting cells 
(APC) into nasal lymphatics (NL) and cervical lymph nodes (CLN). CSF from 
the lumbar subarachnoid space drains to lumbar lymph nodes. iSF from 
the brain parenchyma drains along basement membranes in the walls 
of cerebral capillaries and arteries (blue arrows) to cervical lymph nodes 
adjacent to the internal carotid artery just below the base of the skull. There 
is interchange between CSF and iSF (convective influx/glymphatic system) 
as CSF enters the surface of the brain alongside penetrating arteries.
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trial the biggest clinical improvement was seen in those with 
ARIA,83 suggesting that ARIA may in fact be a marker of effi-
cacy of amyloid clearance, rather than only a deleterious side 
effect. Furthermore, ARIA often causes few clinical symptoms in 
comparison to CAA-ri.5 Thus it is possible that, while inflamma-
tory CAA and ARIA are manifestations of active Aβ clearance, 
sporadic CAA represents a quiescent period of disease, evidence 
of either previous parenchymal clearance or ongoing low-level 
clearance, which like many cases of ARIA may be asymptom-
atic. Better understanding of these processes is essential, for 
extending the future therapeutic use of Aβ immunotherapies and 
for understanding the mechanisms by which ICH occurs in CAA.
ClInICAl ImpACT on CognITIon
CAA: an increasingly recognised cause of cognitive 
impairment
Recent research has expanded understanding of the relationship 
of CAA with cognitive impairment and highlighted effects that 
are separate from those due to AD pathology and macrohaemor-
rhage. A distinct cognitive profile of CAA has been described in 
living people with CAA-related syndromes, and clinical imaging 
studies have begun to unravel the mechanisms by which CAA 
impairs cognition.
Autopsy studies in community-dwelling elderly show that 
CAA pathology is very common in older people, with moderate 
to severe accumulation (present in about a third of aged individ-
uals) associated with impaired cognition and adding to the like-
lihood of dementia even after controlling for the effects of AD 
and other pathologies.89–92 A detailed clinical-pathological study 
showed that moderate and severe CAA is also independently 
associated with accelerated decline in global cognition, and 
specifically processing speed, language skills and episodic 
memory.89 Most recently, two studies report on the neuropsy-
chological profile of CAA in living people with CAA-related 
clinical syndromes (signifying severe CAA pathology).93 94 Both 
studies excluded patients with dementia, and mostly enrolled 
patients after CAA-related ICH. Results were essentially concor-
dant, with prominently impaired processing speed observed in 
both93 94 and a high prevalence of mild cognitive impairment 
(79%).93 These differ from the previously mentioned autopsy 
studies, in which deficits in memory and language were also 
involved; this may be a reflection of the absence of dementia in 
these patient groups. The cognitive profile of CAA in these hospi-
tal-based studies differed from the community autopsy studies in 
that episodic memory, the sine qua non of AD (and mild cogni-
tive impairment due to AD), was relatively preserved.93 Finally, 
community-based studies have shown associations between 
strictly lobar microbleeds and impairments in global cognition 
and visuospatial executive function.95 96 Overall, these studies 
show that cognitive impairment is common in people with CAA, 
with a profile that may be typical for vascular cognitive impair-
ment (especially prior to developing dementia) but also includes 
a broader range of impairment that results in a profile that over-
laps with that of other diseases.
The prospective association of CAA with risk for dementia 
has been further demonstrated by the findings of two longitu-
dinal cohort studies of the risk for dementia following ICH. In 
these prospective cohorts, the incidence of new-onset dementia 
reached 29% (95% CI 23% to 35%) 4.5 years after ICH onset.45 
In line with data on pre-existing dementia in patients with ICH,97 
the risk of incident dementia among non-demented survivors of 
spontaneous ICH was substantial and higher in patients with 
lobar ICH. While ICH characteristics like size and location were 
likely to influence the risk of developing dementia soon after 
ICH,98 predictors of delayed dementia were strongly associated 
with well-known features of CAA: cSS and cerebral microbleeds. 
The effect of so-called ‘silent’ chronic lesions suggests that 
cognitive decline occurring after a lobar ICH is the expression 
of an underlying subtle small vessel-related process rather than 
the sole consequence of acute macro-bleeding. Therefore, to 
prevent cognitive decline in patients with CAA, future studies 
might focus on modifying and monitoring the appearance of 
chronic lesions such as cSS or cerebral microbleeds, rather than 
just trying to avoid macrohaemorrhage. The coexisting issues of 
haemorrhagic lesions and cognition highlight the need for closer 
collaborations between stroke centres and memory centres in the 
field of CAA.
Neuroimaging biomarker studies are beginning to identify 
correlates of cognitive impairment in the absence of new ICH, 
implying additional mechanisms of clinically relevant brain injury 
in CAA. Previous studies showed that cognitive impairment in 
CAA was associated with higher burden WMH of presumed 
vascular origin99 100 and brain atrophy.94 Cortical atrophy may 
result from CAA-related microinfarction that disconnects white 
matter tracts,101 suggesting that ischaemic injury contributes to 
cognitive impairments.102 The global burden of white matter 
disconnection is demonstrated by network analyses derived from 
diffusion-tensor MRI and graph theory methods that consider 
the brain to be an interconnected network. A study of 38 non-de-
mented patients with CAA showed that global network efficiency 
was decreased compared with controls, and that among patients 
with CAA lower global network efficiency explained 34% of the 
variance in processing speed and 29% of the variance in exec-
utive function, without explaining variance in memory.103 Over 
a mean follow-up of 1.3 years, declines in global network effi-
ciency were detectable, particularly for posterior brain network 
connections, and were associated with declining executive func-
tion.104
While the associations between cognitive impairment and 
dementia in CAA (both with and without AD, and in the 
context of ICH) are increasingly recognised, case reports suggest 
that CAA can present with other behavioural and psychiatric 
symptoms, including delirium, depression and personality 
change.105 106 Given the small number of reported cases, it is 
not clear whether CAA is causative in these cases, or simply a 
coincident finding. Further data on the mechanisms behind these 
presentations, as well as their absolute incidence, are needed.
Impact and interaction of CAA in Ad
As well as contributing to cognitive impairment in patients 
with ICH, CAA might have an analogous independent impact 
in AD,89 which is of particular significance because AD and 
CAA frequently coexist.89 90 Recent neuropathological work has 
demonstrated that CAA makes an independent cognitive contri-
bution to AD dementia, even after adjusting for other age-re-
lated pathologies including AD pathology.89 There is evidence 
that patients with familial AD develop WMH up to 6 years 
before estimated symptom onset and that this may be a ‘core 
feature’ of familial AD107; the predominantly parietal and occip-
ital distribution of these WMH are consistent with the distri-
bution seen in sporadic CAA.107 108 Moreover, cortical atrophy, 
an imaging finding previously felt to be primarily representative 
of AD pathology, occurs in CAA even in the absence of coex-
istent AD pathology14; furthermore,  those with strictly lobar 
microbleeds and AD demonstrate more grey matter atrophy and 
greater reductions in glucose metabolism than those without.109 
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These findings together suggest that certain clinical and radio-
logical features that have previously been thought to exclusively 
represent AD pathology may in fact be manifestations of CAA; 
as a consequence, future treatment strategies for AD that do not 
consider the impact of CAA may be less efficacious in amelio-
rating cognitive symptoms.89
The apparent impact of CAA in those with AD as well as those 
with ICH raises questions about the validity of describing CAA 
as either predominantly ‘haemorrhagic’ or ‘non-haemorrhagic’. 
Of these subtypes, the former has been associated with the ApoE 
ε2 allele and haemorrhagic imaging markers of CAA including 
lobar microbleeds and cSS.110 Non-haemorrhagic CAA is asso-
ciated with the presence of ApoE ε4110; ApoE ε4 is also asso-
ciated with capillary-level CAA as well as AD.111 Although it is 
tempting to consider the latter as a ‘cognitive’ CAA given these 
associations, evidence suggests that the situation is more complex 
than this. The presence of capillary CAA does not appear to be 
associated with cognitive decline,89 and although both ApoE ε2 
and ApoE ε4 are associated with CAA, it is ApoE ε4 that is asso-
ciated with more severe CAA on neuropathological examination 
(as defined by Vonsattel grading).111 112 Additionally, ApoE ε4 
has been shown to be associated with cSS in a memory clinic 
population.41 Further data on the cognitive impact of ApoE ε2 in 
CAA, in particular whether it has an effect on cognition beyond 
the direct damage caused by macrohaemorrhage, are needed.
mAnAgemenT And TreATmenT dIlemmAs
Transient focal neurological episodes
The last 5 years have seen a continued development of our 
understanding and recognition of TFNEs, which are estab-
lished as a common clinical feature of CAA. There is a greater 
appreciation of the range of symptoms with which TFNE can 
present, in particular ‘negative’ or ‘transient ischaemic attack 
(TIA)-like’ symptoms such as motor weakness, dysphasia or 
visual loss, which may be present in up to half of all TFNE 
presentations.113 Spreading onset and recurrent stereotyped 
attacks seem to be typical.113 There is increasing evidence that 
TFNE frequently occurs as a result of acute cSAH,113–116 with 
symptoms correlated with the site of cSAH.114 This acute cSAH 
has been shown to evolve (often over weeks to months44) by 
deposition of haemosiderin in superficial cortical layers as cSS, 
a recognised MRI marker of CAA (figure 3).32 114 115 TFNE 
seems to be associated with focal cSS in particular.32 TFNE and 
cSAH both also appear to be associated with an increased risk 
of subsequent ICH.35 113 115 Rather than a direct consequence 
of the individual site of cSAH or cSS, the increased ICH risk 
could be because TFNE (via their association with cSAH and 
cSS) is a marker of overall leptomeningeal CAA severity; indeed, 
there is some evidence that future haemorrhages tend to occur 
in locations distant from sites of cSAH or cSS.114 The mechanism 
by which an acute cSAH results in TFNE remains unknown. 
Electroencephalography (EEG) changes, namely intermittent 
focal slowing, have been demonstrated in a subset of patients 
with TFNE114; this is of interest as similar EEG findings have 
been associated with the cortical spreading depression believed 
to underlie migraine aura.113 114 Cortical spreading depression 
has also been observed in patients with aneurysmal SAH, and is 
believed to contribute to the delayed ischaemic damage seen in 
these patients.117–119 However, EEG changes were only present 
in a small number of patients with TFNE, and it is not clear 
whether all TFNE presentations (for example, limb-jerking) can 
be explained by cortical spreading depression alone; seizure 
activity might play a role in some patients. Although there is 
increasing anecdotal data that antiepileptic and antimigraine 
medications (such as levetiracetam or topiramate) might reduce 
the frequency or severity of TFNE symptoms,44 113 116 they 
may also remit spontaneously; controlled trial data are lacking. 
Recognition of CAA-related TFNE (by assessing the clinical 
features and performing appropriate acute neuroimaging) is crit-
ical to avoid potentially hazardous exposure to antithrombotic 
drugs, the standard treatment for TIAs.
management of patients with CAA with indications for 
antithrombotics or anticoagulants
The thorniest dilemmas in management of patients with CAA 
occur when there is an unrelated indication for antithrombotic 
therapy. Unfortunately, this is all too common because evidence-
based indications for antithrombotic therapy, such as atrial fibril-
lation or vaso-occlusive disease, accrue with age, just as CAA 
does. A study of lobar ICH survivors showed that despite an 
episode of life-threatening bleeding, more than 20% had anti-
thrombotics initiated after hospital discharge.120
With an average ICH recurrence rate in CAA of about 9% 
per year,121 antithrombotic strategies that increase the relative 
risk of ICH by more than about 50% are likely to outweigh any 
antithrombotic-associated reduced risk of thrombosis, even in 
patients with atrial fibrillation, probably causing more harm than 
good. Much of the early data for restarting oral anticoagulation 
(OAC) after an OAC-related ICH came from small hospital 
studies with inconclusive results.122–125 Three larger registry 
studies126–128 have since demonstrated that restarting OAC after 
an OAC-related ICH might be of benefit, with a clear reduction 
Figure 3 imaging findings in CAA-associated TFNe. images from a 
76-year-old patient who presented with migratory left-sided sensory 
symptoms consistent with CAA-associated TFNe. His original CT (A) shows 
a hyperdense area in keeping with an acute cSAH (arrow). Three months 
later he had a similar episode; repeat CT (B) at this time demonstrated 
another acute cSAH nearby (arrow). Subsequent susceptibility weighted 
MRi (C and D) showed widespread disseminated cSS affecting the right 
hemisphere (arrowheads). CAA, cerebral amyloid angiopathy; cSAH, 
convexity subarachnoid haemorrhage; cSS, cortical superficial siderosis; 
TFNe, transient focal neurological episodes.
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in the risk of ischaemic stroke in all cases. With regard to recur-
rent ICH risk, the results are more indeterminate, with one study 
showing a slight risk reduction,126 another no increase in risk127 
and another showing an increased risk.128 A recent meta-anal-
ysis129 including 5306 patients with anticoagulation-associated 
ICH from eight studies (nearly all evaluating treatment with 
vitamin K antagonists) suggested that restarting anticoagulation 
was associated with a lower risk of thromboembolic complica-
tions (pooled relative risk, 0.34; 95% CI 0.25 to 0.45; Q=5.12, 
p for heterogeneity=0.28), with no increased risk of recurrent 
ICH (although with significant heterogeneity; pooled relative 
risk, 1.01; 95% CI 0.58 to 1.77; Q=24.68, p for heteroge-
neity <0.001). There are also some data126 130 131 that restarting 
anticoagulation in those with previous ICH and atrial fibrilla-
tion is associated with reduced mortality. Unfortunately, none of 
these observational studies distinguish between CAA-related and 
non-CAA-related ICH; given the recurrent ICH risk is higher 
in those with CAA,17 121 132 it is difficult to know whether the 
above findings are applicable to these patients. Additionally, 
these studies are retrospective and observational, thus lacking 
randomised comparisons, and may be prone to further inherent 
physician treatment biases about which patients with ICH are 
chosen to resume anticoagulation and which are not. Currently 
we suggest that it is probably not indicated to use warfarin anti-
coagulation in patients with CAA and a history of ICH,133 as 
warfarin reinitiation may increase the risk of recurrent ICH by 
more than fivefold in ICH survivors.123 The risk for new symp-
tomatic haemorrhage in patients with CAA-related TFNE or 
cSAH is not as well defined but probably also substantial and 
similar to that after CAA-ICH35 113; therefore, warfarin antico-
agulation should probably be avoided in these patients as well.
The use of aspirin is an alternate strategy for patients with 
atrial fibrillation and CAA-related ICH, but has limited evidence 
of efficacy for atrial fibrillation-related stroke prevention.134 The 
non-vitamin K antagonist oral anticoagulants (NOACs) have 
proven efficacy in atrial fibrillation-related stroke prevention but 
only half the risk of intracranial haemorrhage as warfarin,135 and 
may thus be a valuable alternative to warfarin in ICH survivors. 
In the only randomised comparison of a NOAC with aspirin, in 
patients considered unsuitable for warfarin, apixaban was more 
effective at preventing thrombotic events with no difference in 
rates of overall bleeding or intracranial bleeding.136 In an MRI 
substudy of AVERROES (Apixaban Versus Acetylsalicylic Acid [ 
to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed 
or Are Unsuitable for Vitamin K Antagonist Treatment),137 the 
number of new microbleeds was also not different between 
patients assigned to apixaban versus aspirin. Finally, the use of 
devices to occlude the left atrial appendage could be considered 
in eligible patients with atrial fibrillation and history of ICH,133 
although the optimal postimplantation antithrombotic strategy 
has not been defined in prospective studies in patients with 
CAA. Further randomised trials of anticoagulation after ICH are 
clearly needed and are underway.138
The risks of antithrombotic therapies in patients with inciden-
tally discovered lobar microbleeds, possibly representing asymp-
tomatic CAA, have been much debated139 but with little evidence 
on which to base decisions. In the general population, partici-
pants with lobar microbleeds have a very low annual risk of ICH 
(only 0.6% over mean 4.9 years of follow-up in one study140); 
however, the degree to which this risk would be increased by 
anticoagulation is uncertain. In patients with ischaemic stroke 
or TIA, cerebral microbleeds increase the risk of both future 
ischaemic stroke and ICH; the absolute risk of ischaemic 
stroke exceeds that of ICH, but in those with more than five 
microbleeds (mainly treated with antiplatelet therapy) these risks 
seem to be finely balanced.141 A scientific statement from the 
American Heart Association142 suggests that routine guideline 
recommended care for atrial fibrillation should be unchanged 
even when lobar microbleeds are present, with a preference for 
NOACs when anticoagulation is indicated. MRI screening prior 
to initiating anticoagulation is of unknown value and unlikely 
to be cost-effective.143 Ongoing cohort studies in patients with 
atrial fibrillation, ischaemic stroke and MRI, treated with OAC, 
will provide better prospective information on microbleeds and 
future ICH risk in this population.144 145
statins
Statin use in patients with, or at risk of, ICH has been controversial 
since the SPARCL (Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels) trial in 4731 patients with recent stroke (due 
to ischaemia or haemorrhage) or TIA found an increased risk of 
recurrent ICH in those taking high-dose atorvastatin (55 ICH vs 
33 in the placebo group; hazard ratio, HR, 1.68, 95% CI 1.09 to 
2.58).146 In multivariable Cox regression, ICH risk was sixfold 
higher in those having a haemorrhagic stroke as the entry event 
(HR 5.65, 95% CI 2.82 to 11.30, p<0.001),146 and the risk of 
ICH was highest in those with SVD (HR 4.99, 95% CI 1.71 to 
14.61).146 147 The only other randomised study to consider the 
effect of statins in patients with stroke (ischaemic stroke) was 
the Heart Protection Study (HPS)148; a meta-analysis combining 
data from SPARCL and HPS found that while statin use was 
protective for ischaemic stroke (relative risk, RR, 0.80, 95% CI 
0.78 to 0.99), the risk for ICH was increased (RR 1.73, 95% CI 
1.19 to 2.50).149
While the data for statins and ICH in general remain 
conflicting,150–159 observational data suggest that statins might 
be particularly associated with ICH in the context of CAA. 
A trend for association between statin use and lobar ICH for 
those with the ApoE ε4/ε4 or ApoE ε2/ε4 genotypes has been 
described,160 and the more recent Multicenter Study on Cere-
bral Haemorrhage in Italy (MUCH-Italy) study161 reported that 
the greatest impact of statins on future ICH risk appears to be 
in those with lobar haemorrhages. A decision analysis suggested 
that statin use in survivors of lobar ICH was associated with a 
reduction in quality-adjusted life years.162 There is also evidence 
for an association between statin use and the presence of lobar 
microbleeds.163 164 Despite the relative paucity of data in this area 
and its clear limitations (most obviously the use of lobar macro-
haemorrhages and microhaemorrhages as surrogate markers for 
CAA, and the absence of information on the influence of statin 
dose), recent decision analyses support caution when prescribing 
statins in those with CAA.151 162 Data from randomised prospec-
tive studies including ICH survivors are needed to improve our 
understanding of the possible risks of statin use in CAA.
Immunotherapy
June 2013 saw the start of the first therapeutic clinical trial 
in CAA, using the humanised monoclonal antibody pone-
zumab.165 166 The antibody, initially trialled in AD,166–168 is of 
interest to the CAA community given its specificity for Aβ40, the 
predominant Aβ subtype in vascular deposits,3 166 and its prom-
ising results in animal models.169 There were questions about 
which outcome markers to use for this relatively short trial,31 as 
well as significant safety concerns given the common occurrence 
of ARIA following Aβ immunotherapy in AD.82 Given that ARIA 
is pathologically characterised by a shift of Aβ into the vascula-
ture and the development of imaging features consistent with 
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CAA,5 85 current recommendations advise excluding patients 
with high microbleed counts from AD immunotherapy trials.170 
However, despite worries that immunotherapy in CAA could 
lead to clinical deteriorations in these patients, ponezumab was 
well tolerated, with no ARIA-like events (Claire Leurent, Pfizer, 
personal communication 2017). The formal results of this study, 
which used occipital vascular reactivity to visual stimulation as a 
primary outcome measure,165 are expected later this year.
WhAT’s nexT For CAA?
In the last 5 years we have seen real advances in our under-
standing of CAA, and there is excitement about potential future 
progress. The planned revision of the current Boston criteria 
to better reflect recent clinical and radiological discoveries is 
underway, and it is expected that any new criteria will address 
the relevance of non-haemorrhagic markers (for example, peri-
vascular spaces in the centrum semiovale), whether the presence 
of deep microbleeds truly excludes a diagnosis of CAA, and 
whether different diagnostic criteria are needed for its haemor-
rhagic and cognitive subtypes. This should improve our ability 
to define disease presence, severity and subtypes, which might 
help guide clinical decision making and future trials with regard 
to antithrombotic, anticoagulant and statin use.
Developing treatments for CAA remains a priority; the 
suggestion that immunotherapy in CAA might be safe opens 
the road for the development of new agents with a similar 
mode of action. Other strategies, for example the drug (R)-1-
[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrroli-
dine-2-carboxylic acid (CPHPC), which targets serum amyloid 
P component, also hold promise.171 However, while the hope 
is that therapies that target vascular amyloid will be successful, 
there is a risk that without significant progress in our knowl-
edge of how and why CAA develops, identifying an effec-
tive treatment will be impossible. For this reason, advances 
in our understanding of CAA pathophysiology and how this 
translates into its clinical and radiological manifestations are 
a crucial development needed to advance the field in future 
years.
Identifying an effective therapeutic approach for CAA might 
have a critical bearing on the treatment of AD; given current 
recommendations excluding those with high microbleed counts 
from AD immunotherapy trials170 and the growing evidence 
that ARIA is common and possibly a marker of treatment effi-
cacy,5 83–86 being able to understand and potentially treat CAA-re-
lated effects could improve safety and increase the number of 
patients with AD eligible for treatment with these agents. This 
raises the possibility of combination immunotherapy, with 
parenchymal and vascular Aβ being targeted at different stages 
of treatment. New evidence on the impact of potentially modi-
fiable risk factors for CAA, in particular blood pressure control, 
is also needed. While a subgroup analysis of PROGRESS (Perin-
dopril Protection Against Recurrent Stroke Study)172 showed 
that those with probable CAA (although with limited diagnostic 
evaluation) had a 77% reduction in ICH with blood pressure 
lowering, there is still no guidance on specific blood pressure 
targets or how aggressively this should be managed in patients 
without macrohaemorrhage. As well as preventing recurrent 
ICH, there is interest in whether blood pressure has an impact 
on the progression and burden of CAA, in a manner analo-
gous to that observed in age-related deep-perforating arteriop-
athy, another common cerebral SVD.173 174 Further randomised 
controlled trials, including the use of neuroimaging surrogate 
markers of CAA, will be important in determining how blood 
pressure control (of both level and variability) might influence 
the natural history of CAA. Other important areas of research 
include the natural history of CAA (both with and without 
macrohaemorrhage), identifying biomarkers for early disease 
and the nature and extent of cognitive impact of CAA in ICH 
and AD.
ConClusIons
The clinical impact of CAA is no longer disputed, and the last 
5 years have witnessed a rapid increase in new knowledge in this 
field. Newly identified biomarkers are improving our diagnostic 
capability and mechanistic understanding, as well as providing 
practical outcome markers in clinical trials. The interaction 
between CAA and AD remains of great interest, both in terms of 
pathological and cognitive implications, and may be key to the 
successful use of immunotherapies in AD and CAA in future. The 
next 5 years promise new and exciting advances with the pros-
pect of earlier, more accurate diagnosis and ultimately rational 
preventive and disease-modifying treatments.
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